Phase 2 Study of Ceritinib as Last-line Therapy in Gastrointestinal Cancers

Share this content:
Researchers are investigating the potential of ceritinib among patients with varying types of advanced gastrointestinal cancers with ALK and ROS1 rearrangement who have no available therapeutic option
Researchers are investigating the potential of ceritinib among patients with varying types of advanced gastrointestinal cancers with ALK and ROS1 rearrangement who have no available therapeutic option

Title: A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies1

Principle Investigator: Christopher Lieu, MD, Criterium Inc

Description: For this single-arm, phase 2 study, researchers are investigating the potential of ceritinib among patients with varying types of advanced gastrointestinal cancers with ALK and ROS1 rearrangement who have no available therapeutic options.

Eligible patients must have been pretreated with cytotoxic chemotherapy and have been diagnosed with colorectal adenocarcinoma, cholangiocarcinoma, esophageal, gastric, hepatocellular, or pancreatic adenocarcinoma. ALK or ROS1 activation must be histologically or cytologically confirmed.

The primary endpoint of the study is the 2-month clinical benefit rate of ceritinib, which is defined as the percentage of patients who have a partial response, complete response, or stable disease. Secondary outcome measures include the number of patients who experience treatment-associated adverse events and 2-month objective tumor response.

The estimated enrollment is 30 patients.

For more study information, including exclusion and inclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02638909.

Status: This study is open and recruiting patients as of September 26, 2017.

This study is sponsored by Criterium Inc in collaboration with Novartis and the University of Colorado, Denver.

Reference

  1. Clinicaltrials.gov. Study of oral ceritinib in patients With ALK and ROS1 activated gastrointestinal malignancies. NCT02638909. https://clinicaltrials.gov/ct2/show/NCT02638909. Accessed September 26, 2017. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters